We extend a big congratulations to our client, Biohaven Ltd., on recently entering into an agreement with Oberland Capital Management LLC for an investment of up to $600 million, of which $250 million was already funded at the end of April 2025. Fundraising in the pharmaceutical sector remains highly competitive and this exceptional round of fundraising is testament to Biohaven’s commitment to high quality innovation and delivering new therapeutics to patients in need.
Although the funding is for use across their entire pipeline, a particular focus will be to support Biohaven’s efforts as they seek FDA approval of troriluzole as the first ever the treatment of spinocerebellar ataxia (SCA), a fatal genetic degenerative brain disease thought to affect 150,000 people in the United States. As part of our work on their portfolio for this asset, we are very pleased to have already secured a granted patent for Biohaven at the EPO that is directly related to this treatment.
The team at Mewburn Ellis LLP includes Thomas Wolter and Andrew Pitts, who collaborate closely with Biohaven’s IP team to implement their European intellectual property strategy. It is a real pleasure to work with such a committed and hard-working in-house IP team that punches well above their weight.
Our sincere congratulations go out to the teams at Biohaven and Oberland Capital. We look forward to continuing to work with Biohaven across their entire portfolio as they seek to hit their next key milestones in the journey towards improving patients’ lives with new medicines.
